Katsukunya J, Soko N, Naidoo J, Rayner B, Blom D, Sinxadi P
Int J Hypertens. 2024; 2023:9919677.
PMID: 38633331
PMC: 11022520.
DOI: 10.1155/2023/9919677.
Lee F, Islahudin F, Ali Nasiruddin A, Gafor A, Wong H, Bavanandan S
J Pers Med. 2021; 11(4).
PMID: 33808503
PMC: 8066991.
DOI: 10.3390/jpm11040252.
Lidberg K, Annalora A, Jozic M, Elson D, Wang L, Bammler T
Sci Rep. 2021; 11(1):4722.
PMID: 33633318
PMC: 7907328.
DOI: 10.1038/s41598-021-84194-w.
Galaviz-Hernandez C, Lazalde-Ramos B, Lares-Assef I, Macias-Salas A, Ortega-Chavez M, Rangel-Villalobos H
Front Pharmacol. 2020; 11:638.
PMID: 32477124
PMC: 7232668.
DOI: 10.3389/fphar.2020.00638.
Hua Y, Esche J, Hartmann M, Maser-Gluth C, Wudy S, Remer T
Endocrine. 2019; 67(2):442-448.
PMID: 31813102
DOI: 10.1007/s12020-019-02151-0.
Genetics and ESKD Disparities in African Americans.
Umeukeje E, Young B
Am J Kidney Dis. 2019; 74(6):811-821.
PMID: 31606237
PMC: 7373097.
DOI: 10.1053/j.ajkd.2019.06.006.
Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer.
Buck E, Sprick M, Gaida M, Grullich C, Weber T, Herpel E
Oncol Lett. 2019; 17(4):3890-3898.
PMID: 30881507
PMC: 6403523.
DOI: 10.3892/ol.2019.10043.
Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee H, Byeon J, Kim Y, Lee C, Choi C, Jang C
Eur J Clin Pharmacol. 2018; 74(11):1417-1426.
PMID: 30039199
DOI: 10.1007/s00228-018-2522-5.
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.
Chen L, Prasad G
Pharmgenomics Pers Med. 2018; 11:23-33.
PMID: 29563827
PMC: 5846312.
DOI: 10.2147/PGPM.S107710.
The time-dependent effects of St John's wort on cytochrome P450, uridine diphosphate-glucuronosyltransferase, glutathione S-transferase, and NAD(P)H-quinone oxidoreductase in mice.
Yang J, Liu Y, Huang C, Ueng Y
J Food Drug Anal. 2018; 26(1):422-431.
PMID: 29389584
PMC: 9332643.
DOI: 10.1016/j.jfda.2017.01.004.
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Lolodi O, Wang Y, Wright W, Chen T
Curr Drug Metab. 2017; 18(12):1095-1105.
PMID: 28558634
PMC: 5709240.
DOI: 10.2174/1389200218666170531112038.
Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
Zong Y, Wang Z, Zhou W, Zhou W, Ma T, Huang Z
World J Pediatr. 2017; 13(5):421-426.
PMID: 28540692
DOI: 10.1007/s12519-017-0035-4.
The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos M, Caritis S, Jablonski K, Reddy U, Sorokin Y, Manuck T
Am J Obstet Gynecol. 2017; 217(3):369.e1-369.e9.
PMID: 28522317
PMC: 5896763.
DOI: 10.1016/j.ajog.2017.05.019.
CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population.
Fisher D, Plange-Rhule J, Moreton M, Eastwood J, Kerry S, Micah F
J Hum Hypertens. 2016; 30(12):778-782.
PMID: 27334520
DOI: 10.1038/jhh.2016.25.
The Uromodulin Gene Locus Shows Evidence of Pathogen Adaptation through Human Evolution.
Ghirotto S, Tassi F, Barbujani G, Pattini L, Hayward C, Vollenweider P
J Am Soc Nephrol. 2016; 27(10):2983-2996.
PMID: 26966016
PMC: 5042664.
DOI: 10.1681/ASN.2015070830.
Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country.
Kumara W, Perera T, Dissanayake M, Ranasinghe P, Constantine G
BMC Res Notes. 2013; 6:373.
PMID: 24053215
PMC: 3848873.
DOI: 10.1186/1756-0500-6-373.
CYP3A5 polymorphism, amlodipine and hypertension.
Zhang Y, Zuo X, Huang Z, Cai J, Wen J, Duan D
J Hum Hypertens. 2013; 28(3):145-9.
PMID: 23863802
DOI: 10.1038/jhh.2013.67.
Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.
Bains R, Kovacevic M, Plaster C, Tarekegn A, Bekele E, Bradman N
BMC Genet. 2013; 14:34.
PMID: 23641907
PMC: 3655848.
DOI: 10.1186/1471-2156-14-34.
Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.
Rais N, Hussain A, Chawla Y, Kohli K
Exp Ther Med. 2013; 5(2):527-532.
PMID: 23404385
PMC: 3570147.
DOI: 10.3892/etm.2012.842.
Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights K, Rowland A, Miners J
Br J Clin Pharmacol. 2013; 76(4):587-602.
PMID: 23362865
PMC: 3791982.
DOI: 10.1111/bcp.12086.